Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival
Fast on the heels of a key success for small cell lung cancer, Roche’s Tecentriq team at Genentech has scored another frontline win for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
